Yanling WangSr. Director of Synthetic Biology, Protein Expression at HenliusSpeaker
Profile
25+ years’ experience in biopharmaceutical and biotechnology industry
18+ years of leadership in biologics drug discovery/development: from target, pre-IND profiling and development, IND nomination, to process development and FDA/EMA filling. Fully involved with more than 30 IND/NDA projects.
In-depth experiences in building comprehensive expression platforms for therapeutic antibodies and proteins like mAb, Fab, scFv, VHH antibodies, especially for hard-to-express asymmetrical bi-specific, multi-specific immnocytokine and enzyme fusion proteins. Two corresponding publications in peer reviewed journal received wide recognition.
Possess extensive domain expertise in immuno-oncology cultivated through numerous projects. Deep involvement in the discovery, engineering, and CMC development of pioneering drugs such as PD-1, CTLA-4, TIGIT, Lac3, and OX40. Core contributor to the development of commercialized biosimilars including Rituxan, Herceptin, Avastin and Humira, etc.
Agenda Sessions
Address the CMC Development Challenges of Bispecifics, Including Immunocytokines Combining Antibodies with Cytokines, and Fusion Proteins Combining Antibodies with Enzymes
, 9:00amView SessionBeyond mAbs: The Next Wave of Therapeutic Innovation for a New Era
, 1:30pmView Session